Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-06835919 in NAFLD
NCT03256526Phase 2Completed
- Sponsor
- Pfizer
- Start
- Sep 2017
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of PF-06835919 in non-alcoholic fatty liver disease (NAFLD) (3 arms), sponsored by Pfizer. Primary endpoint: Percent Change From Baseline in Whole Liver Fat at Week 6. Started Sep 2017; status: completed.
02
Drugs
PF-06835919
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT03256526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03256526.